New share news | Hemei Pharmaceuticals submitted an application to the Hong Kong Stock Exchange. Its core product Mufemilast has been approved for commercialization in China.

According to the Zhitong Finance APP, as disclosed by the Hong Kong Stock Exchange on December 1, Ganzhou Hemei Pharmaceutical Co., Ltd. (referred to as: Hemei Pharmaceutical) has submitted an application to the Hong Kong Stock Exchange Main Board, with Guotou Securities International as its exclusive sponsor. Hemei Pharmaceuticals has made significant efforts in identifying, developing, and commercializing biotechnology and other candidate drug products. Its comprehensive research and development capabilities have been validated by successful track records, including the successful development of the core product Mufemilast, which has been approved in China for the treatment of moderate to severe psoriasis. As of the last practicable date, the company has developed a strong product pipeline consisting of seven candidate drugs.